Skip to main content

Advertisement

SpringerLink
Log in

Intravitreal ranibizumab (Lucentis®) for the treatment of myopic choroidal neovascularization

  • Retinal Disorders
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Background

Macular choroidal neovascularization (CNV) is one of the most vision-threatening complications of myopia, which can lead to severe vision loss. The purpose of this study was to evaluate the safety and efficacy of intravitreal ranibizumab in the treatment of myopic CNV.

Methods

We conducted a prospective, consecutive, interventional study of patients with subfoveal or juxtafoveal CNV secondary to pathologic myopia (PM) treated with intravitreal injection of ranibizumab in the Jules Gonin University Eye Hospital from June 2006 to February 2008. Best-corrected visual acuity (BCVA), optical coherence tomography (OCT), and fluorescein angiography (FA) were performed at baseline and monthly for all patients. Indications for retreatment were loss in BCVA associated either with persistent leakage from CNV shown on FA, and/or evidence of CNV activity on OCT.

Results

The study included 14 eyes of 14 patients. The mean spherical equivalent refractive error was −12.5 (range, −8.0 D to −16.0 D). Mean time of follow-up was 8.4 months (range from 3 to 16 months, SD: 3). The mean number of intravitreal injections administered for each patient was 2.36 (SD 1.5). The mean initial visual acuity (VA) was 0.19 decimal equivalent (logMAR: 0.71, SD: 0.3). A statistically significant improvement to a mean VA of 0.48 decimal equivalent (log-MAR:0.32, SD: 0.25) was demonstrated at the final follow-up. VA improved by a mean of 3.86 (SD 2.74) lines. Nine patients (64%) demonstrated a gain of 3 or more lines. Mean central macular thickness (CMT) measured with OCT was 304 μm (SD: 39) at the baseline, and was reduced significantly at the final follow-up to 153 μm (SD: 23). Average CMT reduction was 170 μm (SD: 57). No injection complications or drug-related side effects were noted during the follow-up period.

Conclusions

In this small series of eyes with limited follow-up, intravitreal ranibizumab was a safe and effective treatment for CNV secondary to PM, resulting in functional and anatomic improvements.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Hampton GR, Kohen D, Bird AC (1983) Visual prognosis of disciform degeneration in myopia. Ophthalmology 90:923–926

    PubMed  CAS  Google Scholar 

  2. Miller DG, Singerman LJ (2001) Natural history of choroidal neovascularization in high myopia. Curr Opin Ophthalmol 12:222–224. doi:10.1097/00055735-200106000-00014

    Article  PubMed  CAS  Google Scholar 

  3. Avila MP, Weiter JJ, Jalkh AE, Trempe CL, Pruett RC, Schepens CL (1984) Natural history of choroidal neovascularization in degenerative myopia. Ophthalmology 91:1573–1581

    PubMed  CAS  Google Scholar 

  4. Cohen SY, Laroche A, Leguen Y, Soubrane G, Coscas GJ (1996) Etiology of choroidal neovascularization in young patients. Ophthalmology 103:1241–1244

    PubMed  CAS  Google Scholar 

  5. Blinder KJ, Blumenkranz MS, Bressler NM, Bressler SB, Donato G, Lewis H, Lim JI, Menchini U, Miller JW, Mones JM, Potter MJ, Pournaras C, Reaves A, Rosenfeld P, Schachat AP, Schmidt-Erfurth U, Sickenberg M, Singerman LJ, Slakter JS, Strong HA, Virgili G, Williams GA (2003) Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial–VIP report no. 3. Ophthalmology 110:667–673. doi:10.1016/S0161-6420(02)01998-X

    Article  PubMed  Google Scholar 

  6. Secretan M, Kuhn D, Soubrane G, Coscas G (1997) Long-term visual outcome of choroidal neovascularization in pathologic myopia: natural history and laser treatment. Eur J Ophthalmol 7:307–316

    PubMed  CAS  Google Scholar 

  7. Mateo C, Moreno J, Rosales G, Lechuga M, Castillo R, Vaz F, Corcostegui B (2004) Two-year results of macular translocation with scleral infolding in myopic choroidal neovascularisation. Semin Ophthalmol 19:29–42. doi:10.1080/08820530490520013

    Article  PubMed  Google Scholar 

  8. Fujii GY, Humayun MS, Pieramici DJ, Schachat AP, Au Eong KG, de Juan E Jr (2001) Initial experience of inferior limited macular translocation for subfoveal choroidal neovascularization resulting from causes other than age-related macular degeneration. Am J Ophthalmol 131:90–100. doi:10.1016/S0002-9394(00)00769-8

    Article  PubMed  CAS  Google Scholar 

  9. Ruiz-Moreno JM, de la Vega C (2001) Surgical removal of subfoveal choroidal neovascularisation in highly myopic patients. Br J Ophthalmol 85:1041–1043. doi:10.1136/bjo.85.9.1041

    Article  PubMed  CAS  Google Scholar 

  10. Kobayashi H, Kobayashi K (2000) Radiotherapy for subfoveal neovascularisation associated with pathological myopia: a pilot study. Br J Ophthalmol 84:761–766. doi:10.1136/bjo.84.7.761

    Article  PubMed  CAS  Google Scholar 

  11. Liu DT, Lam DS, Chan WM (2004) Selective occlusion of subfoveal choroidal neovascularization in pathologic myopia using a new technique of ingrowth site treatment. Am J Ophthalmol 137:383 author reply 383-386. doi:10.1016/j.ajo.2003.10.015

    Article  PubMed  Google Scholar 

  12. Costa RA, Calucci D, Teixeira LF, Cardillo JA, Bonomo PP (2003) Selective occlusion of subfoveal choroidal neovascularization in pathologic myopia using a new technique of ingrowth site treatment. Am J Ophthalmol 135:857–866. doi:10.1016/S0002-9394(02)02257-2

    Article  PubMed  Google Scholar 

  13. Montero JA, Ruiz-Moreno JM (2007) Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study. Br J Ophthalmol 91:131–133. doi:10.1136/bjo.2006.106526

    Article  PubMed  Google Scholar 

  14. Chan WM, Lai TY, Wong AL, Liu DT, Lam DS (2007) Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study. Br J Ophthalmol 91:174–179. doi:10.1136/bjo.2006.103606

    Article  PubMed  Google Scholar 

  15. Rakic JM, Lambert V, Devy L, Luttun A, Carmeliet P, Claes C, Nguyen L, Foidart JM, Noel A, Munaut C (2003) Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci 44:3186–3193. doi:10.1167/iovs.02-1092

    Article  PubMed  Google Scholar 

  16. Otani A, Takagi H, Oh H, Koyama S, Ogura Y, Matumura M, Honda Y (2002) Vascular endothelial growth factor family and receptor expression in human choroidal neovascular membranes. Microvasc Res 64:162–169. doi:10.1006/mvre.2002.2407

    Article  PubMed  CAS  Google Scholar 

  17. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419–1431. doi:10.1056/NEJMoa054481

    Article  PubMed  CAS  Google Scholar 

  18. Chan WM, Lai TY, Liu DT, Lam DS (2007) Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study. Ophthalmology 114(12):2190–2196. doi:10.1016/j.ophtha.2007.03.043

    Article  PubMed  Google Scholar 

  19. Hernandez-Rojas ML, Quiroz-Mercado H, Dalma-Weiszhausz J, Fromow-Guerra J, Amaya-Espinosa A, Solis-Vivanco A, Reyna-Castelan E, Abraham-Marin M, Martinez-Castellanos MA, Aiello LP (2007) Short-term effects of intravitreal bevacizumab for subfoveal choroidal neovascularization in pathologic myopia. Retina 27:707–712

    PubMed  Google Scholar 

  20. Laud K, Spaide RF, Freund KB, Slakter J, Klancnik JM Jr (2006) Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab. Retina 26:960–963. doi:10.1097/01.iae.0000240121.28034.c3

    Article  PubMed  Google Scholar 

  21. Mandal S, Venkatesh P, Sampangi R, Garg S (2007) Intravitreal bevacizumab (Avastin) as primary treatment for myopic choroidal neovascularization. Eur J Ophthalmol 17:620–626

    PubMed  CAS  Google Scholar 

  22. Nguyen QD, Shah S, Tatlipinar S, Do DV, Anden EV, Campochiaro PA (2005) Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia. Br J Ophthalmol 89:1368–1370. doi:10.1136/bjo.2005.066431

    Article  PubMed  CAS  Google Scholar 

  23. Sakaguchi H, Ikuno Y, Gomi F, Kamei M, Sawa M, Tsujikawa M, Oshima Y, Kusaka S, Tano Y (2007) Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia. Br J Ophthalmol 91:161–165. doi:10.1136/bjo.2006.099887

    Article  PubMed  CAS  Google Scholar 

  24. Tewari A, Dhalla MS, Apte RS (2006) Intravitreal bevacizumab for treatment of choroidal neovascularization in pathologic myopia. Retina 26:1093–1094. doi:10.1097/01.iae.0000254896.78766.74

    Article  PubMed  Google Scholar 

  25. Yamamoto I, Rogers AH, Reichel E, Yates PA, Duker JS (2007) Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia. Br J Ophthalmol 91:157–160. doi:10.1136/bjo.2006.096776

    Article  PubMed  Google Scholar 

  26. Steinbrook R (2006) The price of sight–ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med 355:1409–1412. doi:10.1056/NEJMp068185

    Article  PubMed  CAS  Google Scholar 

  27. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ (2007) Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 114:2179–2182. doi:10.1016/j.ophtha.2007.09.012

    Article  PubMed  Google Scholar 

  28. Rosenfeld PJ (2007) Intravitreal Avastin for choroidal neovascularisation in pathological myopia: the controversy continues. Br J Ophthalmol 91:128–130. doi:10.1136/bjo.2006.101337

    Article  PubMed  CAS  Google Scholar 

  29. Holladay JT (1997) Proper method for calculating average visual acuity. J Refract Surg 13:388–391

    PubMed  CAS  Google Scholar 

  30. Ohno-Matsui K, Yoshida T, Uetama T, Mochizuki M, Morita I (2003) Vascular endothelial growth factor upregulates pigment epithelium-derived factor expression via VEGFR-1 in human retinal pigment epithelial cells. Biochem Biophys Res Commun 303:962–967. doi:10.1016/S0006-291X(03)00446-7

    Article  PubMed  CAS  Google Scholar 

  31. Ohno-Matsui K, Morita I, Tombran-Tink J, Mrazek D, Onodera M, Uetama T, Hayano M, Murota SI, Mochizuki M (2001) Novel mechanism for age-related macular degeneration: an equilibrium shift between the angiogenesis factors VEGF and PEDF. J Cell Physiol 189:323–333. doi:10.1002/jcp.10026

    Article  PubMed  CAS  Google Scholar 

  32. Tong JP, Chan WM, Liu DT, Lai TY, Choy KW, Pang CP, Lam DS (2006) Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol 141:456–462. doi:10.1016/j.ajo.2005.10.012

    Article  PubMed  CAS  Google Scholar 

  33. Kourlas H, Abrams P (2007) Ranibizumab for the treatment of neovascular age-related macular degeneration: a review. Clin Ther 29:1850–1861. doi:10.1016/j.clinthera.2007.09.008

    Article  PubMed  CAS  Google Scholar 

  34. Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, Shams N (2008) Randomized, double-masked, sham-controlled trial of Ranibizumab for neovascular age-related macular degeneration: PIER study year 1. Am J Ophthalmol 145:239–248. doi:10.1016/j.ajo.2007.10.004

    Article  PubMed  CAS  Google Scholar 

  35. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432–1444. doi:10.1056/NEJMoa062655

    Article  PubMed  CAS  Google Scholar 

  36. Nagpal M, Nagpal K, Nagpal PN (2007) A comparative debate on the various anti-vascular endothelial growth factor drugs: pegaptanib sodium (Macugen), ranibizumab (Lucentis) and bevacizumab (Avastin). Indian J Ophthalmol 55:437–439

    Article  PubMed  Google Scholar 

  37. Mordenti J, Cuthbertson RA, Ferrara N, Thomsen K, Berleau L, Licko V, Allen PC, Valverde CR, Meng YG, Fei DT, Fourre KM, Ryan AM (1999) Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 27:536–544. doi:10.1177/019262339902700507

    Article  PubMed  CAS  Google Scholar 

  38. Gaudreault J, Fei D, Beyer JC, Ryan A, Rangell L, Shiu V, Damico LA (2007) Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits. Retina 27:1260–1266

    PubMed  Google Scholar 

  39. Ferrara N, Damico L, Shams N, Lowman H, Kim R (2006) Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 26:859–870. doi:10.1097/01.iae.0000242842.14624.e7

    Article  PubMed  Google Scholar 

  40. Olsen TW (2007) Treatment of exudative age-related macular degeneration: many factors to consider. Am J Ophthalmol 144:281–283. doi:10.1016/j.ajo.2007.05.005

    Article  PubMed  Google Scholar 

  41. Sayanagi K, Ikuno Y, Soga K, Wakabayashi T, Tano Y (2008) Marginal crack after intravitreal bevacizumab for myopic choroidal neovascularization. Acta Ophthalmol (Copenh) 85:50–54

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hôpital Ophtalmique Jules Gonin, University of Lausanne, 15 Av. de France, CH-1004, Lausanne, Switzerland

    Lazaros Konstantinidis, Irmela Mantel, Jean-Antoine C. Pournaras, Leonidas Zografos & Aude Ambresin

Authors
  1. Lazaros Konstantinidis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Irmela Mantel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jean-Antoine C. Pournaras
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Leonidas Zografos
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Aude Ambresin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aude Ambresin.

Additional information

Financial Support: None

Rights and permissions

Reprints and permissions

About this article

Cite this article

Konstantinidis, L., Mantel, I., Pournaras, JA.C. et al. Intravitreal ranibizumab (Lucentis®) for the treatment of myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 247, 311–318 (2009). https://doi.org/10.1007/s00417-008-0995-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-008-0995-0

Keywords

Search

Navigation